Clinical Trial

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Study acronym: SAFIR3LibHERty
Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the efficacy of trastuzumab deruxtecan in terms of progression-free survival (PFS).
Protocol Amendment History 1 change
notable Trial sites expanded: 34 -> 38 locations 2026-08-04
Trial Details
NCT Number NCT06680596
Lead Sponsor UNICANCER
Collaborators: AstraZeneca, Breast Cancer Research Foundation
Conditions Breast Cancer Metastatic, Breast Cancer Stage IV
Enrollment 80 participants
Start Date 2025-07-30
Primary Completion 2028-08-01 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-03